Back to Oncology
Oncologyv2021Evidence-Based

Immune-Related Adverse Events for GI Toxicity - Colitis

Grades severity of colitis secondary to immune checkpoint inhibitor therapy and provides management recommendations

Clinical Input Parameters

stools/day
Range: 0 — 20 stools/day
Clinical Assessment
Awaiting Parameters
irae grade
—grade
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Immune-Related Adverse Events for GI Toxicity - Colitis is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within oncology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Grading based on stool frequency increase over baseline, presence of incontinence, functional impact, and hospitalization needs: Grade 1 (<4 stools/day increase), Grade 2 (4-6 stools/day increase), Grade 3 (≥7 stools/day increase, incontinence, limiting self-care), Grade 4 (life-threatening consequences)

Clinical Pearls & Practice Notes

  • Based on Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0
  • Most frequently occurs 5-10 weeks after ICPi treatment initiation
  • More common with anti-CTLA-4 agents (ipilimumab) than anti-PD-1/PD-L1
  • Grade 2+ requires holding ICPi and gastroenterology consultation
  • Corticosteroids are first-line treatment for grade 2-4 colitis
  • Infliximab considered for steroid-refractory cases (avoid if perforation risk)
  • CTLA-4 agents should be permanently discontinued for grade 3-4 colitis
  • Anti-PD-1/PD-L1 agents may be resumed after grade 2-3 resolution
  • Monitor for complications: perforation, bleeding, sepsis, toxic megacolon
  • Colonoscopy helpful for diagnosis and severity assessment
  • Stool studies should exclude infectious causes (C. diff, CMV, parasites)
  • Dietary modifications: avoid high-fiber foods, dairy, caffeine, alcohol
  • Supportive care includes hydration, electrolyte monitoring, nutritional support
  • Mortality rate up to 1-2% for severe cases, mainly from perforation/sepsis

Evidence & Literature Citations

  1. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018 Jun 10;36(17):1714-1768. doi: 10.1200/JCO.2017.77.6385.
  2. Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, et al. NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. J Natl Compr Canc Netw. 2020 Mar 1;18(3):230-241. doi: 10.6004/jnccn.2020.0012.
  3. Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Oncol. 2018 Dec 1;4(12):1721-1728. doi: 10.1001/jamaoncol.2018.3923.
  4. Gupta A, De Felice KM, Loftus EV Jr, Khanna S. Systematic review: colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther. 2015 Aug;42(4):406-17. doi: 10.1111/apt.13281.

Score Interpretation Ranges

Tier 11 – 1 pts

Mild - Increase of <4 stools per day over baseline

Tier 22 – 2 pts

Moderate - Increase of 4-6 stools per day over baseline

Tier 33 – 3 pts

Severe - Increase of ≥7 stools per day, incontinence, limiting self-care

Tier 44 – 4 pts

Life-threatening - Life-threatening consequences, urgent intervention required

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.